RenovaRo Inc. Files 8-K Report
Ticker: LNAI · Form: 8-K · Filed: May 24, 2024 · CIK: 1527728
| Field | Detail |
|---|---|
| Company | Renovaro Inc. (LNAI) |
| Form Type | 8-K |
| Filed Date | May 24, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, company-update
TL;DR
RenovaRo Inc. (formerly Enochian) filed an 8-K on 5/24/24 covering other events and financials.
AI Summary
On May 24, 2024, RenovaRo Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." The company, formerly known as Enochian Biosciences Inc. and Renovaro Biosciences Inc., is incorporated in Delaware and operates in the Pharmaceutical Preparations sector.
Why It Matters
This 8-K filing provides an update on RenovaRo Inc.'s corporate activities and financial reporting, which is crucial for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not appear to contain any immediately alarming or significant negative news.
Key Players & Entities
- RenovaRo Inc. (company) — Registrant
- Enochian Biosciences Inc. (company) — Former Company Name
- Renovaro Biosciences Inc. (company) — Former Company Name
- May 24, 2024 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing for RenovaRo Inc.?
The filing is for "Other Events" and "Financial Statements and Exhibits" as of May 24, 2024.
What were RenovaRo Inc.'s previous names?
RenovaRo Inc. was formerly known as Enochian Biosciences Inc. and Renovaro Biosciences Inc.
In which state is RenovaRo Inc. incorporated?
RenovaRo Inc. is incorporated in Delaware.
What is RenovaRo Inc.'s Standard Industrial Classification (SIC) code?
RenovaRo Inc.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.
What is the filing date of this 8-K report?
The filing date of this 8-K report is May 24, 2024.
Filing Stats: 481 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-05-24 10:19:01
Key Financial Figures
- $0.0001 — ch Registered Common Stock, par value $0.0001 per share RENB The Nasdaq Stock Mar
Filing Documents
- e5707_8-k.htm (8-K) — 26KB
- e5707_ex99-1.htm (EX-99.1) — 11KB
- 0001731122-24-000877.txt ( ) — 211KB
- renb-20240524.xsd (EX-101.SCH) — 3KB
- renb-20240524_lab.xml (EX-101.LAB) — 33KB
- renb-20240524_pre.xml (EX-101.PRE) — 22KB
- e5707_8-k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On May 24, 2024, Renovaro Inc. (the " Company ") issued a press release. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in this Item 8.01 and in Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that Section or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits . (d) Exhibits. Exhibit No. Exhibit 99.1 Press Release dated May 24, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RENOVARO INC. By: /s/ Simon Tarsh Name: Simon Tarsh Title: Interim Chief Financial Officer Date: May 24, 2024